DURHAM, North Carolina, Feb. 20, 2025 (GLOBE NEWSWIRE) — Die Society for Clinical Research Sites (SCRS) und Fortrea (Nasdaq: FTRE), ein führendes globales Auftragsforschungsinstitut (Contract Research Organization, [...] Read more »
Society for Clinical Research Sites (SCRS) and Fortrea Partner to Advance Collaboration in Clinical Research
DURHAM, N.C., Feb. 20, 2025 (GLOBE NEWSWIRE) — The Society for Clinical Research Sites (SCRS) and Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), are pleased to announce Fortrea’s [...] Read more »
Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives to Support the Global Development and Commercialization of Therapies for Autoimmune Diseases
– Advancing Phase 2 and Phase 3 trials of obexelimab, a unique CD–19 x FcγRIIb inhibitor of B cell function–
–Topline results from Phase 2 Trial in [...] Read more »
Sabin Vaccine Institute Delivers Marburg Vaccines to Combat Outbreak in Rwanda
[Caption] Sabin Vaccine Institute delivered 700 doses of its Marburg vaccine to Rwanda on Oct. 5, 2024.
WASHINGTON, Oct. 05, 2024 (GLOBE NEWSWIRE) — The Sabin Vaccine Institute has provided [...] Read more »
Minovia Therapeutics Announces FDA Clearance of IND Application for a Phase Ib Clinical Trial of MNV-201 in Low Risk Myelodysplastic Syndrome
MNV–201 is a mitochondrial cell therapy product composed of autologous hematopoietic stem cells enriched with allogeneic mitochondria
In pre–clinical studies, MNV–201 [...] Read more »
Entera Bio Reports Q2 2024 Financial Results and Provides Business Updates
JERUSALEM , Aug. 09, 2024 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and small therapeutic proteins, [...] Read more »
Sabin Vaccine Institute Begins Phase 2 Clinical Trial for Sudan Ebolavirus Vaccine
Laboratory at Makerere University Walter Reed Project, where Sabin’s Phase 2 Sudan ebolavirus vaccine clinical trial begins this month.
Read more »
CSL Behring Announces First Two Patients Treated with HEMGENIX® (etranacogene dezaparvovec) Gene Therapy for Hemophilia B in Europe
MARBURG, Germany, July 04, 2024 (GLOBE NEWSWIRE) — Global biotechnology leader Read more »